SVNT - Savient Pharmaceuticals, Incorporated
As seen in the Media
At Ockham, we combine our proprietary stock valuation metrics with key snippets of pundit commentary.On this page you can find commentary specific to Savient Pharmaceuticals, Incorporated through our product RazorWire. RazorWire listens to shows like Mad Money, Cavuto, Money For Breakfast and many more. RazorWire also reads the best financial blogs. Then RazorWire slices just the snippets that discuss stocks covered in the Ockham Universe and brings those snippets to our clients.
Please use this page to keep up with what is being said about Savient Pharmaceuticals, Incorporated in the media. Or, visit our homepage for information on other stocks in the news right now.
Savient Pharmaceuticals, Incorporated (SVNT) Discussed on Fox Business's The Opening Bell on Fox Business
Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.
Ford shares up 10% already in the early going here op optimism over july sales, senior execs saying that the auto maker on track to report its first monthly sales gain in two years. And number one, SAVIENT PHARMACEUTICALS saying that the food and drug administration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here.
“… inistration declined to approve on its drug for chronic gout. The approval was widely expected by shareholders here. …”
Savient Pharmaceuticals, Incorporated (SVNT) Discussed on Fox Business's The Opening Bell on Fox Business
Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.
Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching,
“… Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching, …”